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Simple Summary: Anaplastic large cell lymphoma (ALCL) is a lymphoid malignancy considered
to be derived from T cells. Currently, two types of systemic ALCL are distinguished: anaplastic
lymphoma kinase (ALK)-positive and ALK-negative ALCL. Although ALK+ and ALK− ALCL differ
at the genomic and molecular levels, various key biological and molecular features are highly similar
between both entities. We have developed the concept that both ALCL entities share a common
principle of pathogenesis. In support of this concept, we here describe a common deregulation of
CD74, which is usually not expressed in T cells, in ALCL. Ligation of CD74 induces cell death of
ALCL cells in various conditions, and an anti-CD74-directed antibody-drug conjugate efficiently
kills ALCL cell lines. Furthermore, we reveal expression of the proto-oncogene and known CD74
interaction partner MET in a fraction of ALCL cases. These data give insights into ALCL pathogenesis
and might help to develop new treatment strategies for ALCL.
Abstract: In 50–60% of cases, systemic anaplastic large cell lymphoma (ALCL) is characterized
by the t(2;5)(p23;q35) or one of its variants, considered to be causative for anaplastic lymphoma
kinase (ALK)-positive (ALK+) ALCL. Key pathogenic events in ALK-negative (ALK−) ALCL are
less well defined. We have previously shown that deregulation of oncogenic genes surrounding
the chromosomal breakpoints on 2p and 5q is a unifying feature of both ALK+ and ALK− ALCL
and predisposes for occurrence of t(2;5). Here, we report that the invariant chain of the MHC-II
complex CD74 or li, which is encoded on 5q32, can act as signaling molecule, and whose expression
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in lymphoid cells is usually restricted to B cells, is aberrantly expressed in T cell-derived ALCL.
Accordingly, ALCL shows an altered DNA methylation pattern of the CD74 locus compared to
benign T cells. Functionally, CD74 ligation induces cell death of ALCL cells. Furthermore, CD74
engagement enhances the cytotoxic effects of conventional chemotherapeutics in ALCL cell lines, as
well as the action of the ALK-inhibitor crizotinib in ALK+ ALCL or of CD95 death-receptor signaling
in ALK− ALCL. Additionally, a subset of ALCL cases expresses the proto-oncogene MET, which
can form signaling complexes together with CD74. Finally, we demonstrate that the CD74-targeting
antibody-drug conjugate STRO-001 efficiently and specifically kills CD74-positive ALCL cell lines
in vitro. Taken together, these findings enabled us to demonstrate aberrant CD74-expression in
ALCL cells, which might serve as tool for the development of new treatment strategies for this
lymphoma entity.
Keywords: CD74; invariant chain; MHC-II; T cell lymphoma; ALK translocation
1. Introduction
Systemic anaplastic large cell lymphoma (ALCL), a subgroup of peripheral T cell lym-
phomas (PTCL), is characterized by large atypical cells and expression of the TNF receptor
family member CD30 [1–3]. Among systemic ALCLs, the current 2016 WHO classification
distinguishes two entities: anaplastic lymphoma kinase (ALK)-positive (ALK+) ALCL,
which is in most cases characterized by the t(2;5)(p23;q35) resulting in the expression of the
oncogenic NPM-ALK fusion protein and represents approx. 50–60% of all ALCL cases; and
ALK-negative (ALK−) ALCL, which lacks t(2;5) and ALK expression [4]. Despite recent
progress [5,6], key pathogenic events in ALK− ALCL are still less clarified. Although
phenotypically highly similar [1], both ALCL entities show differences with respect to
genomic aberrations, gene expression profile [7–9], miRNA expression pattern [10] and
prognosis, which is unfavorable in ALK− ALCL [11]. Given the rather poor prognosis of
subgroups of ALK− ALCL patients and of refractory or relapsed ALCL patients, alternative
treatment strategies are required in particular for this group of patients.
Despite differences at the genomic and molecular levels, ALK+ and ALK− ALCL
share various key biological and molecular features [7,12–17]. We have previously devel-
oped the concept that deregulation of genes surrounding the ALCL-characteristic putative
breakpoints on chromosomes 2p and 5q might be similarly important for ALCL lymphoma-
genesis as the resulting translocation itself [14,15,18]. In this context, we identified an
ALCL-specific deregulation of breakpoint-surrounding genes with transforming capacity,
including the oncogenic tyrosine-kinase receptor CSF1R or the activator protein-1 (AP-1)
family member Fos-related antigen 2 (FRA2) [14].
In an extension of said work, we demonstrate here in ALCL an unexpected expression
of CD74 (encoded on 5q32; also known as the invariant chain of major histocompatibility
complex [MHC]-II, li), regardless of t(2;5). CD74 belongs to the family of single-pass type II
membrane proteins, serves as chaperone for MHC-II molecules in antigen-presenting cells
and occupies the MHC-II binding groove to prevent inappropriate binding of peptides.
To allow for antigen presentation, CD74 is degraded, and its fragment class-II-associated
invariant chain peptide (CLIP) remains bound to the MHC-II binding groove, which
is ultimately removed to permit peptide binding and subsequent antigen presentation
(for a recent review, see [19]). Initially thought to show an expression pattern largely
restricted to B cells and to be localized intracellularly [20–22], CD74 expression has been
demonstrated to appear on the cell surface and to be present on antigen-presenting cells,
such as macrophages or dendritic cells, as well as certain solid malignancies including
breast and gastrointestinal cancers [19,21,23–25]. In contrast to B cells, T cells usually lack
CD74 expression, and CD74 has previously been reported only on cutaneous T cell-derived
lymphoma cell lines as well as certain T cell subsets following activation [21,24,26,27]. Only
recently, CD74 expression has been analyzed on a broad lymphoma panel including B and
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T cell lymphoma subtypes [28]. Apart from its function as an MHC-II chaperone, CD74 can
act as a signaling molecule, forming receptor complexes with, e.g., CD44, chemokine (C-X-C
motif) receptor 4 (CXCR4) and the proto-oncogene MET [29–33]. Upon activation of CD74
by binding of its ligand, macrophage migration-inhibitory factor (MIF), or by antibody
stimulation, signaling is activated, resulting either in enhanced survival and proliferation or
induction of growth arrest and cell death depending on the cellular context [34–37]. CD74
activation thereby interferes with NF-κB, MAPK, Akt and MET activation [32,33,35,38].
The consistent expression of CD74 on normal and transformed B cells, its rapid in-
ternalization, as well as growth-inhibitory and death-inducing effects in vitro on B cell
non-Hodgkin lymphoma (B-NHL) cells, brought CD74 into focus as a therapeutic tar-
get [39]. Therefore, unconjugated and drug-conjugated monoclonal anti-CD74-antibodies
are currently being investigated in clinical trials for the treatment of B-NHL [40–42]. We
here describe expression of CD74 on T cell-derived ALCL and show that targeting of
CD74 strongly affects the viability of ALCL cell lines, suggesting that CD74 serves as a
therapeutic target in ALCL.
2. Materials and Methods
2.1. Cell Lines and Culture Conditions
ALCL (Karpas 299 (in the following referred to as K299), SU-DHL-1, DEL, JB6, all
ALK+; Mac-1, Mac-2A, FE-PD, DL40, all ALK−) and T cell leukemia-derived (Jurkat, KE-37,
Molt-14, H9) cell lines, the classical Hodgkin lymphoma-derived cell line L428, as well as
the pro-B lymphoblastic leukemia cell line Reh, were cultured as previously described [14].
Cell line identity was confirmed by short tandem repeat (STR) analysis. Where indicated,
cells were cultured in the presence of sodium azide-free anti-CD74 antibody (sc20062L;
Santa Cruz Biotechnology, Heidelberg, Germany), the respective IgG1 isotype control (IC;
sc-3877L; Santa Cruz), IgG(Fc)-specific F(ab′)2-fragments (115-006-071; Dianova, Hamburg,
Germany), the chemotherapeutics vincristine or etoposide (both Calbiochem, Darmstadt,
Germany), the ALK-inhibitor crizotinib (PF-02341066, kindly provided by Pfizer, San
Diego, CA, USA) or the respective DMSO control (Carl Roth, Karlsruhe, Germany), the
agonistic anti-CD95 antibody CH-11 (IM1504; Coulter-Immunotech, Krefeld, Germany) or
the respective IgM control (290-010; Biomol, Hamburg, Germany), or the MET inhibitors
Foretinib (S1111; Selleckchem, München, Germany) and JNJ-38877605 (S1114; Selleckchem)
at the indicated concentrations. In addition, cells were treated with the CD74-targeting ADC
STRO-001 or, as a control, ADC GFP-SC236 targeting GFP (both from Sutro Biopharma)
at the indicated concentrations. The LD50 was determined using non-linear regression in
Prism v8. Peripheral mononuclear cells were purified from peripheral blood of healthy
donors according to standard protocols. The use of human material was approved by
the Local Ethics Committee of the Charité–Universitätsmedizin Berlin, and performed in
accordance with the Declaration of Helsinki.
2.2. RNA Preparation and RT-PCR Analyses
Total RNA preparation was performed as previously described [14]. For RT-PCR
analyses, cDNA synthesis was performed with the 1st Strand cDNA Synthesis Kit (AMV;
Roche Diagnostics, Mannheim, Germany). Semi-quantitative RT-PCR analyses were per-
formed as described. Primers used for RT-PCR analyses were as follows: CD74 sense (s)
5′-GACAGTCACCTCCCAGAACC, CD74 antisense (as) 5′-GGCAGATAGTTGCCGTTCTC;
GAPDH s 5′-ATGCTGGCGCTGAGTAC, GAPDH as 5´-TGAGTCCTTCCACGATAC; MET
s 5′-ATCGATCTGCCATGTGTGC, MET as 5′-CACATATGGTCAGCCTTGTCC; CD44 s
5′-AATATAACCTGCCGCTTTGC, CD44 as 5′-CAGGTCTCAAATCCGATGCT; MIF s 5′-
CCGAGAAGTCAGGCACGTAG, MIF as 5′-ATAGTTGATGTAGACCCTGTCCG; CXCR4 s
5′-GCCGACCTCCTCTTTGTCAT, CXCR4 as 5′-TAGTAAGGCAGCCAACAGGC. All PCR
products were verified by sequencing.
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2.3. Immunofluorescence and Flow Cytometry, Analysis of Apoptosis and Light Microscopy
For the analysis of CD74 cell surface expression, cells were incubated with monoclonal
antibody to CD74 (sc-20062 or sc-6262; both from Santa Cruz), monoclonal antibody to
MET (MAB3582; R&D Systems, Wiesbaden, Germany) or the respective isotype control
(MAB002; R&D Systems), followed by incubation with a phytoerythrin (PE)-conjugated
F(ab′)2 fragment (115-116-071; Dianova). For the analysis of primary lymphoid cells, in-
direct staining for CD74 was performed in a first step as described above, followed by
incubation with APC-labeled anti-CD19 (C7224; Dako, Hamburg, Germany) or anti-CD4
(IM2468; Beckman Coulter, Krefeld, Germany) antibodies. Immunofluorescence was ana-
lyzed using a FACSAria flow cytometer and CELLQuest software (Becton Dickinson). The
percentage of viable and apoptotic cells was determined by Annexin V-FITC/propidium
iodide (PI) double staining (Bender MedSystems) and flow cytometry using a FACSAria
flow cytometer. Cells double negative for Annexin V-FITC and PI were considered as viable
cells. For light microscopy, a Leica CTR6000 microscope equipped with a Leica DFC350FX
camera was used.
2.4. Western Blot Analyses
Whole-cell extract preparation and Western blot analyses were performed as previ-
ously described [14]. For Western blot analyses, 30 µg of whole cell extracts were used.
The following primary antibodies were used: anti-CD74 (sc-20062 and sc-6262; both Santa
Cruz), anti-MET (D1C2; Cell Signaling Technology, Frankfurt (Main), Germany), anti-
poly[ADP-ribose](PARP)-1 (#9542; Cell Signaling Technology), cleaved PARP (Asp214)
(#9541, Cell Signaling Technology), anti-β-actin (A5316; Sigma-Aldrich, Taufkirchen, Ger-
many). Membranes were incubated with horseradish peroxidase-conjugated secondary
antibodies. Bands were visualized using an enhanced chemiluminescence system (Amer-
sham Pharmacia Biotech, Freiburg, Germany).
2.5. Immunohistochemistry (IHC)
The detection of CD74 protein in formalin-fixed and paraffin-embedded tissue sections
was performed employing the anti-CD74 antibodies sc-20062 and sc-6262 (both Santa Cruz)
at a dilution of 1:1000 after a 20 min treatment in EDTA buffer (Retrieval solution 2;
EDTA-buffer pH 8.8 at 98 ◦C for 20 min). Bound antibody was visualized using the alkaline
phosphatase anti-alkaline phosphatase method and FastRed as chromogen (DAKO) or, after
peroxidase blocking, DAB-chromogen. For c-MET detection, the prediluted anti-total c-Met
(clone SP44) rabbit monoclonal antibody was obtained from Ventana (Ventana Medical
System). Immunostaining was carried out according to the manufacturer´s protocol on the
BenchMark Ultra platform from Ventana utilizing the ultraView detection kit.
2.6. DNA Methylation Analyses Using Illumina Infinium Arrays
DNA methylation measurements were performed after modification with the EZ DNA
Methylation kit (ZymoResearch, Irvine, CA, USA) using either Infinium® HumanMethyla-
tion450 (450K) or Infinium® MethylationEPIC (EPIC) BeadChips (Illumina Inc., San Diego,
CA, USA). Moreover, published and publicly available array-based DNA methylation data
were mined (see Supplementary Materials). DNA methylation values from primary ALCL
were generated in-house or obtained from Hassler et al. [16]. In addition, ALK positive
(SU-DHL-1, K299, JB6) and negative (FE-PD, Mac-2A) ALCL cell lines as well as T-ALL
(CCRF-CEM, Jurkat, MOLT-3 and MOLT-4) cell lines were investigated (all obtained from
DSMZ, Germany). Beside neoplastic samples, the study cohort was complemented with
publicly available data from various cell populations covering T- and B-lineage differen-
tiation as well as from monocytes and macrophages (for references, see Supplementary
Materials). Included cell types were hematopoietic stem cells, pre B-cells, immature B-cells,
naïve B-cells, tonsillar naïve B-cells, germinal center founder cells, germinal center derived
B-cells, early non class-switched B-cell, non class-switched memory B-cells, class-switched
memory B-cells, splenic marginal zone B-cells, tonsillar plasma cells, bone marrow plasma
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B-cells and various T cell subpopulations. For the analyses, raw idat files were processed
using the minfi package within the R statistical program (www.R-project.org, accessed on
31 August 2020). Subsequently, beta values were calculated representing the percentage
of DNA methylation at a certain cytosine base. For downstream analyses, rs loci, loci on
gonosomes and loci with a detection p value of >0.01 were excluded from further analysis.
Finally, 15 CpG loci mapping to the CD74 gene locus were extracted from the dataset and
visualized as a heatmap using the OMICS Explorer 3.6 (Qlucore; Lund, Sweden).
2.7. Statistics
Statistical analyses were performed in R v2.9.1 (http://www.r-project.org/, accessed
on 23 September 2021) and graphPad Prism Version 5.0. For statistical analyses of cell
death induction, numbers of viable cells per sample were fitted using a generalized linear,
negative binominal model with a log-link function. For experiments with combinatorial
treatments, all treatments were specified as factors with respective number of factor levels.
For every treatment combination, one main-effect and one interaction-effect model were
calculated. p values were adjusted for multiple testing using Tukey’s honestly significant
difference test.
3. Results
3.1. Aberrant CD74 Expression in ALCL Cell Lines
Analyzing the expression of genes that are located in the same chromosome regions
of the putative t(2;5)(p23;q35) breakpoints in ALCL, we identified in ALCL an aberrant
expression of the CD74 gene (Figure 1) that is located on 5q32. To this end, we used a panel
of ALK+ and ALK− ALCL cell lines and non-ALCL T cell-derived control cell lines already
used in our previous studies [13–15,17]. Robust CD74 mRNA expression was observed in
all ALCL cell lines independent of their ALK expression status, except for SU-DHL-1 cells,
whereas it was absent in the T cell control cell lines (Figure 1A, upper panel; Figure S2).
Using different CD74 antibodies, we confirmed strong CD74 protein expression in ALCL
cell lines by immunoblotting (Figure 1A, lower panel; Figures S1A and S2), demonstrat-
ing multiple bands that most likely reflect the expression of different splice variants and
glycosylation levels [19]. In antigen-presenting cells, CD74 is often found intracellularly
with low expression levels on the cell surface due to rapid internalization and intra-
cellular degradation [39]. However, in all ALCL cell lines with CD74 expression (see
Figures S1A and S2), we observed robust CD74 protein expression on the cell surface by
flow cytometry (Figure 1B and Figure S1B).
3.2. CD74 Expression in Human Lymphocytes and Primary ALCL Cases
To confirm our cell line data, we analyzed lymphoid cells from peripheral blood of
healthy donors, normal lymphoid tissue and primary ALCL samples by flow cytometry
and immunohistochemistry (IHC; Figure 1C,D and Figure S1C, and Table 1). Our analyses
confirmed the restriction of CD74 expression, among lymphoid cells, to the B cell com-
partment. Thus, in tissues of non-neoplastic human palatine tonsils, only B cells (and in
accordance with the known expression pattern, macrophages and dendritic cells) stained
positive, whereas T cells were negative for CD74 (Figure 1C, upper panel). Similarly, in the
analysis of CD74 expression by extracellular flow cytometry on mononuclear cells from
peripheral blood of healthy donors, only CD19+ B cells were positive for CD74, whereas
CD4 T cells (the putative cellular compartment of ALCL origin) lacked CD74 expression
(Figure 1C, lower panel; Figure S1C). Next, we evaluated a series of 35 primary human
ALK+ and 21 ALK− ALCL cases for CD74 expression by IHC (Figure 1D and Table 1). These
analyses confirmed CD74 expression, albeit at different expression levels and frequently
with a predominantly cytoplasmic staining, in all ALCL cases analyzed, independent of
ALK expression (Table 1). In summary, these data demonstrate that CD74 is aberrantly
expressed in, and is a unifying feature of, ALK+ and ALK− ALCL.
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Figure 1. CD74 expression in ALCL. (A) Analysis of CD74 mRNA (upper panel) and protein (lower panel; antibody sc-6262)
expression in various ALK+ and ALK− ALCL as well as T cell control cell lines, as indicated. The expression levels of
GAPDH and of β-actin were analyzed as controls, respectively. Note, that various CD74 protein bands of different sizes
are detectable. (B) Cell surface expression analysis of CD74 in two ALK+ (K299, JB6) and two ALK− (FE-PD, Mac-2A)
ALCL cell lines by extracellular flow cytometry (antibody sc-20062). Open histogram, CD74 staining; filled histogram,
isotype control (IC). (C) Physiological CD74 protein expression in the human B cell compartment. Upper panel, CD74
immunohistochemistry (IHC) in normal human tonsillar tissue. Note that the B cell compartment including the germinal
center strongly stains for CD74 (brown signal), whereas the T cell compartment lacks CD74 expression. Lower panels,
expression analyses of CD74 on T and B cells of human peripheral blood. Left, CD74 and CD4 double-staining of human
peripheral blood mononuclear cells (PMNC). Note, that CD4-positive cells (upper left quadrant) do not stain for CD74. Right,
CD74 and CD19 double-staining of human PMNC of peripheral blood. Note that CD19-positive cells do express CD74
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(upper right quadrant). (D) Representative CD74 IHC analyses of two primary human ALK+ (upper panel, strong staining;
center, weak staining with prominent staining of the Golgi area) cases and one ALK− (lower panel) ALCL case. CD74 signal
is in red. Scale bars: upper panel 100 µm, center and lower panel 50 µm. (E) Heatmap showing DNA methylation levels at
15 CpG loci associated with the gene CD74 in primary ALCL samples (n = 16) and cell lines (SU-DHL-1, K299, JB6, FE-PD,
Mac-2A), T-ALL cell lines (CCRF-CEM, Jurkat, MOLT 3 and MOLT 4), monocytes (n = 23), and macrophages (n = 9) as
well as various non-malignant T- and B-cell subpopulations. Columns represent samples and rows depict loci. The loci are
ordered according to their genomic position.
Table 1. Staining in ALK+ and ALK− ALCL.
Lymphoma Entity No. of Cases
IHC Staining Intensity
Absent + +/++ ++ ++/+++ +++
ALCL ALK+ 35 0 8 15 11 1 0
ALCL ALK− 21 0 3 8 5 4 1
The percentage of positive ALCL cells in each case was unrelated to the staining intensity and was as follows:
among the ALK+ ALCL cases, 100% of the lymphoma cells stained positive in 14, 70–90% in another 14, 50–70%
in 3, and <50% in 4; among ALK− ALCL cases, 100% of the lymphoma cells stained positive in 13, 70–90% in 5,
and <50% in 3. Staining intensities are indicated as follows: +, weak; ++, intermediate; +++, strong.
3.3. DNA Methylation Analyses of the CD74 Locus in ALCL
In order to investigate whether altered DNA methylation could affect expression of
CD74 in ALCL, array-based DNA methylation data of primary ALCL samples and ALCL
cell lines were mined, and the DNA methylation levels of 15 CpGs at the CD74 locus
were determined (Figure 1E). Findings were compared to those in various B- and T-cell
subpopulations, monocytes, macrophages and T-ALL cell lines as well (Figure 1E). In
contrast to all controls, we observed a strong DNA methylation around the transcription
start site (TSS) in the T-ALL cell lines and in SU-DHL-1. Several loci associated with
the 3′UTR, parts of the gene body and 5′ of the gene (TSS1500) were generally strongly
methylated, but lost DNA methylation during the progression of B-cell differentiation,
in line with the restricted CD74 expression pattern in mature B-cells [20–22,43]. Notably,
the same CpGs showed decreased DNA methylation in several primary ALCL samples
and ALCL cell lines compared to normal T-cell subsets, further supporting unusual CD74
expression in this putative T cell-derived lymphoma entity.
3.4. Induction of Apoptosis in ALCL following CD74 Ligation
CD74 is currently being explored as a therapeutic target particularly in B-NHL [40–42].
We reasoned that CD74 might also be a suitable target structure in ALCL. To this end,
we explored the effects of CD74 ligation on the viability of ALCL cell lines (Figure 2
and Figure S1D). We cultured various ALCL cell lines in the presence of a monoclonal
anti-CD74 or IgG control antibody without or, to enforce crosslinking and to mimic the
presence of Fcγ-receptor-bearing cells, with Fcγ-specific F(ab′)2-fragments (Figure 2A,B).
We measured induction of cell death by Annexin V-FITC/PI staining and subsequent
flow cytometry at various times (24 h, 48 h and 72 h). Cell clustering was observed in
samples treated with anti-CD74 in combination with F(ab′)2-fragment as documented by
light microscopy (Figure 2A, right panels). Importantly, in CD74+ ALCL cell lines, we
observed a time- and dose-dependent induction of apoptosis (Figure 2A, left panel, and
Figure 2B; Figure S1D). Although the extent of cell death varied between ALCL cell lines,
all CD74 positive cell lines showed a significant degree of apoptotic cell death (Figure 2B).
In contrast, SU-DHL-1 cells, which do not express CD74 (see Figure 1A; Figure S2), were
not affected by anti-CD74 treatment (Figure 2B).
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Figure 2. Induction of apoptosis of ALCL cell lines following CD74 ligation. (A) K299 cells were left untreated, or treated
for 48 h with 20 µg F(ab′)2-fragments (F(ab′)2), 5 µg anti-CD74 (α-CD74) or the respective IgG1 isotype control (α-IgG1), or
anti-CD74 or anti-IgG1 in combination with F(ab′)2-fragments, as indicated. Left, flow cytometry analyses of the respectively
treated cells following Annexin V-FITC and PI-staining. The percentage of viable, Annexin V-FITC/propidium iodide (PI)
double-negative cells is indicated. Right, transmitted-light microscopy of the cells. Note that strong clustering of cells is
observed following treatment with anti-CD74 in combination with F(ab′)2. One of three independent experiments is shown.
(B) Various ALK+ and ALK− cell lines were left untreated (black columns), or were treated for 72 h with anti-CD74 in
combination with F(ab′)2 (open columns), or, as control, anti-IgG1 in combination with F(ab′)2 (grey columns) as described
in (A). Note that SU-DHL-1 cells, which lack CD74 expression, do not respond to CD74 ligation. One of four independent
experiments is shown. Error bars denote SDs. ***, p < 0.001. ns, not significant.
3.5. CD74 Ligation Sensitizes ALCL Cell Lines for Various Apoptosis-Inducing Agents
We next investigated whether CD74 ligation sensitizes ALCL cells for induction
of cell death by other pharmacological agents or death-receptor engagement (Figure 3).
First, we explored the combined treatment of cross-linked anti-CD74 and conventional
chemotherapeutics with respect to a synergistic induction of cell death (Figure 3A). Here,
we focused on etoposide and vincristine, which are both used for the treatment of ALCL [2].
ALK+ K299 and ALK− Mac-2A cells were treated either with each chemotherapeutic, or
crosslinked anti-CD74 alone using concentrations that only moderately induce cell death,
or the respective combinations (Figure 3A). In these experiments, the combined treatment
with each of the chemotherapeutics with anti-CD74 led to enhanced cell death induction
(Figure 3A).
Cancers 2021, 13, 5012 9 of 18
Figure 3. CD74 ligation sensitizes ALCL cell lines for various apoptosis-inducing stimuli. (A) In-
creased induction of apoptosis following CD74 ligation in combination with conventional chemother-
apeutics. K299 and Mac-2A cells were left untreated, or were treated for 48 h with etoposide (Eto),
vincristine (Vin), anti-CD74 in combination with F(ab′)2 (α-CD74+F(ab′)2; K299 with 2 µg F(ab′)2
and 0.5 µg anti-CD74, Mac-2A with 8 µg F(ab′)2 and 2 µg anti-CD74) or the respective combinations,
as indicated. In all panels of this figure, the percentage of viable cells (Annexin V-FITC and PI double
negative) is shown following Annexin V-FITC/PI staining and flow cytometry. Note that significant
interaction effects (indicated by an ‘i’ in the respective columns) are observed in both cell lines by
the combined treatment with chemotherapeutics and crosslinked α-CD74. (B) Increased induction
of apoptosis following CD74 ligation and concomitant treatment with the ALK-inhibitor crizotinib.
The ALK+ cell lines K299 and JB6 were left untreated or were treated for 24 h (K299) or 48 h (JB6)
with crizotinib (crizo), anti-CD74 in combination with F(ab′)2 (α-CD74+F(ab′)2; K299 with 4 µg
F(ab′)2 and 1 µg anti-CD74, JB6 with 10 µg F(ab′)2 and 2.5 µg anti-CD74), or crizotinib together
with crosslinked anti-CD74, as indicated. Note that in both cell lines, significant interaction effects
are observed by treatment with crizotinib in combination with crosslinked α-CD74. (C) Increased
induction of apoptosis following CD74 ligation in combination with anti-CD95 in ALK– ALCL cells.
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The ALK+ cell line K299 and the ALK– cell line Mac-2A were left untreated, or were treated for 40 h
with an agonistic CD95 antibody (α-CD95; K299 500 ng/mL; Mac-2A 50 ng/mL) or the respective
isotype control (α-IgM), anti-CD74 in combination with F(ab′)2 (α-CD74+F(ab′)2; K299 with 4 µg
F(ab′)2 and 1 µg anti-CD74, Mac-2A with 8 µg F(ab′)2 and 2 µg anti-CD74), or the respective
combinations, as indicated. Note that a significant interaction effect is observed in Mac-2A but not in
K299 cells. Error bars denote SDs. ***, p < 0.001. ns, not significant. i, significant interaction effect.
For each experimental approach, one of three independent experiments is shown.
Second, we analyzed the effects of a combined treatment of the CD74 antibody with
the ALK-inhibitor crizotinib. The latter has been successfully used for the treatment of
ALK+ non-small cell lung cancer (NSCLC) [44] and is an effective treatment option for
ALK+ ALCL patients [45]. To this end, the ALK+ cell lines K299 and JB6 were treated
with each agent alone at concentrations that induced approx. 40% cell death, or with both
agents in combination (Figure 3B). Combined treatment resulted in a substantial synergistic
induction of cell death of around 80 % of cells (Figure 3B).
Third, we observed that a combined treatment of crosslinked anti-CD74 with an
agonistic CD95 antibody led to a synergistic increase in the induction of apoptosis in ALK–
Mac-2A cells, while each substance alone induced cell death only in a moderate fashion
under the conditions applied (Figure 3C, right panel). In ALK+ ALCL cell lines, treatment
with anti-CD95 had no effect on cell viability and did not enhance cell death induction by
crosslinked anti-CD74 antibody (Figure 3C, left panel).
3.6. Expression of MET in ALCL
A number of CD74 interaction partners involved in CD74 signaling have been de-
scribed, including CD44, the CD74 ligand MIF, the oncogenic tyrosine-kinases receptor
MET and the C-X-C motif chemokine receptor CXCR4 [29,31,33,46]. Expression analyses in
our cell line panel demonstrated that all putative interaction partners are expressed at least
in a subset of ALCL cell lines (Figure 4 and Figure S1E). For further analysis, we focused on
the receptor tyrosine kinase MET given that it has high oncogenic potential and can be tar-
geted by small molecule inhibitors already in clinical use [47] (Figure 4). Interestingly, MET
mRNA (Figure 4A, upper panel; Figure S2) and protein (Figure 4A, lower panel; Figure S2)
expression analyses revealed a robust MET expression in all ALK+ ALCL cell lines, whereas
ALK− ALCL cell lines lacked MET expression. In addition, MET expression on the cell
surface of ALK+ ALCL cell lines was confirmed by flow cytometry (Figure 4B). MET im-
munohistochemistry on 11 ALK+ and 5 ALK– ALCL primary tissue samples (Figure 4C,D)
revealed MET positivity, although moderate, in 6 out of 11 ALK+ and 2 out of 5 ALK–
ALCL cases. Direct interactions between CD74 and MET have previously been described
in other cell types [33]. However, despite various immunoprecipitation approaches, we
were unable to detect direct interactions of these proteins in ALCL cell lines. Functionally,
we tested the effect of the MET inhibitors Foretinib as well as JNJ-38877605 on the ALK+
ALCL cell lines K299 and JB6, both with MET expression, and on the ALK− ALCL cell
line FE-PD and the T control cell line Jurkat, both the latter without MET expression, for
induction of cell death. Both inhibitors did not alter viability of these cell lines.
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Figure 4. Expression of MET in ALCL. (A) Analysis of MET mRNA (upper panel) and protein (lower panel) expression in
various ALK+ and ALK– ALCL as well as T cell control cell lines, as indicated. The expression levels of GAPDH and of
PARP-1 were analyzed as controls, respectively. Note that two MET bands are detectable at the protein level, corresponding
to the precursor protein pro-MET (upper band) as well as MET (lower band). (B) Cell surface expression analysis of MET in
four ALK+ ALCL cell lines (K299, SU-DHL-1, DEL, JB6) by extracellular flow cytometry. L428 cells with a known MET
expression [48] were included as positive control, Reh cells as negative control. Open histogram, MET staining; filled
histogram, isotype control (IC). (C) Examples of MET IHC of an ALK+ ALCL case (upper panel) and an ALK– ALCL case
(lower panel) with moderate tumor cell positivity. Note the cytoplasmic and partially membranous staining of the large
ALCL cells. Magnification, 40X. (D) Results of MET IHC analyses in ALK+ and ALK− ALCL. *, the percentage of positive
ALCL cells among the cases was as follows: in 2 cases 60% of the lymphoma cells stained positive (in both cases including
membranous staining), in 1 case 10%, in 2 cases 5%, in 1 case single positive cells. **, the percentage of positive ALCL cells
among the cases was as follows: in 1 case 40%, in 1 case 10%. Staining intensity is indicated as follows: +, weak.
3.7. The CD74-Targeting Antibody-Drug Conjugate STRO-001 Efficiently Kills ALCL Cell Lines
Given the robust expression of CD74 on ALCL, and the rapid internalization of CD74,
we reasoned that targeting CD74 by specific antibody-drug conjugates might be a possible
treatment strategy for ALCL. To this end, we treated various ALCL and non-ALCL cell
lines in vitro with the recently developed antibody-drug conjugate STRO-001, which is
composed of an aglycosylated anti-CD74 IgG1 human antibody conjugated to a non-
cleavable linker-maytansinoid warhead [42] (Figure 5A and Figure S3). Cells were treated
with STRO-001 or, as a control, an isotype-matched ADC targeting GFP (GFP-SC236). As
determined after 72 h, at concentrations below 5 µg/mL STRO-001 efficiently induced cell
death of all the CD74-postive ALCL cell lines K299, JB6, FE-PD and Mac-2A, whereas no
similar cell death induction was observed in the non-ALCL T cell control cell lines Jurkat
and KE-37. The isotype-matched control ADC GFP-SC236 did not affect viability of any
of the cell lines (Figure 5A and Figure S3). Furthermore, we analyzed whole cell extracts
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following treatment with STRO-001 or GFP-SC236 by immunoblotting for PARP-1 cleavage
using antibody specific to cleaved PARP Asp214 (Figure 5B, left panels; Figure S3) as well
as antibody recognizing both full-length PARP and PARP cleavage products (Figure 5B,
right panels; Figure S3). These analyses in K299, Mac-2A and FE-PD cells revealed PARP-
1 cleavage by STRO-001 but not by ADC GFP-SC236 or in CD74-negative Jurkat cells,
suggesting specific induction of apoptosis by STRO-001 in the ALCL cell lines. Induction
of apoptotic cell death was in addition demonstrated by the increase in Annexin V-positive
K299 (Figure 5C and Figure S3) and FE-PD (Figure 5D and Figure S3) cells following
STRO-001 treatment, but was not observed following treatment with the control ADC or
treatment of CD74-negative Jurkat cells (Figure 5E and Figure S3).
Figure 5. Induction of apoptotic cell death by the CD74-targeting antibody-drug conjugate (ADC) STR-001. (A) Left, the
indicated ALCL cell lines (K299, JB6, FE-PD, Mac-2; all CD74 positive) as well as the T cell control cell lines Jurkat and KE-37
(both CD74 negative) were treated with various concentrations of the CD74-targeting ADC STRO-001 (red lines) or, as a
Cancers 2021, 13, 5012 13 of 18
control, an isotype-matched ADC recognizing GFP (GFP-SC236; blue lines), as indicated. After 72 h, induction of cell death
was determined by PI staining and flow cytometry. The percentage of viable cells is indicated. Right, indication of the LD50
for STRO-001 for the various cell lines. Note that below 5 µg/mL, specifically ALCL cells are killed by ADC-STRO-001,
and that the control ADC GFP-SC236 does not exert cytotoxicity on any of the cell lines. One out of three independent
experiments is shown. (B) K299, Mac-2A, FE-PD and Jurkat cells were left untreated (0 h), or treated for 24 and 48 h
with STRO-001 or, as a control, GFP-SC236. At the indicated times, whole cell extracts were prepared and analyzed by
immunoblotting using antibody specifically recognizing cleaved PARP-1 (Asp214) (left panels) or antibody recognizing
full-length PARP-1 and its large cleavage product (the latter marked by *; right panels). Note that an increase in cleaved
PARP-1 is only detected in ALCL cell lines treated with STRO-001. One out of three independent experiments is shown.
(C–E) K299 (C), FE-PD (D) and Jurkat (E) cells were left untreated (control, left) or treated for 48 h with STRO-001 (right) or,
as a control, GFP-SC236 (center). Thereafter, cells were analyzed by Annexin V-FITC/PI-staining for induction of apoptotic
cells. The percentages of cells in the respective quadrants are indicated. Note that an increase in Annexin V-FITC-positive
cells is only detectable in ALCL cell lines treated with STRO-001. One out of three independent experiments is shown.
4. Discussion
Based on our previously developed pathogenic concept that ALK+ and ALK− ALCL
share a common molecular basis of transformation [14,17,18], we report here the identifica-
tion of deregulated CD74 expression as a further candidate gene in support of this view.
Since its initial discovery, the expression of CD74 has been studied particularly in various
B cell compartments as well as B cell- and epithelial cell-derived malignancies [19,39].
Among hematopoietic cells, these analyses identified CD74 expression as a unifying feature
of antigen-presenting cells or their malignant counterparts, being most prominent in cells
of B cell origin. In contrast, except for subpopulations after activation, T cells usually
lack CD74 expression [21,27,49]. CD74 expression in T cell-derived malignancies has been
previously reported for one Sézary syndrome cell line [24], and only recently has CD74
been analyzed in various lymphoma subtypes including T cell-derived malignancies [28].
Remarkably, apart from B-NHL of various subtypes, ALCL showed the most consistent
expression pattern. We here provide further evidence that CD74 expression is a common
feature of T cell-derived ALK+ and ALK− ALCL, which might at least in part be due
to an altered DNA methylation pattern of the CD74 gene locus in ALCL. In a previous
report on pediatric ALCL, CD74 staining could not be detected on ALCL cells [50]. The
reason for that might primarily be methodical differences; a less possible explanation is
that pediatric ALCL, which in most cases is ALK+, differs from adult ALK+ ALCL with
respect to CD74 expression.
Effects of CD74 engagement have been intensively studied in B cells, demonstrating
diverse consequences such as induction of cellular proliferation, survival or cell death
depending on the cell type and differentiation stage [19,34,35,51]. In a number of B cell-
derived malignancies, preclinical models confirmed the efficacy of anti-CD74 targeting
as a therapeutic principle [39,42]. Furthermore, combinatory treatment approaches using
anti-CD74 together with anti-CD20 antibodies resulted in enhanced induction of cell death
as shown for mantle cell lymphoma (MCL) cells [51]. Therefore, anti-CD74 antibodies are
currently being tested in clinical trials for the treatment of patients with B cell malignan-
cies [39,52] and might represent a broad treatment option for these disease entities. In
contrast, for T cell-derived malignancies, antigens with similarly broad expressed patterns
suitable for targeted treatment strategies are rare. Only recently has the approval of armed
anti-CD30-targeting antibodies for the treatment of ALCL patients [53,54] demonstrated
the power of immunotherapeutic approaches also for these malignancies. The consistent
expression of CD74 in ALCL in combination with our functional data suggest that targeting
CD74 should be further explored in T cell malignancies. Thus, CD74 belongs to the few
druggable targets shared between cells of B and T cell origin, and it has to be determined
whether preclinical in vitro and in vivo data as well as results from clinical studies obtained
in B-NHL can be transferred to T cell malignancies. Whether targeting of CD74 might act
synergistically together with CD30-targeting antibodies such as brentuximab vedotin has
to be investigated in future studies.
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We can only speculate about the biological function of the aberrantly expressed CD74
(and expression of CTIIA and MHC-II family members at least in ALCL cell lines) in ALCL.
Obviously, in vivo, CD74 expression in ALCL does not result in cell death as observed
following enforced antibody-mediated ligation. The biological function of aberrant CD74
expression and associated signaling in ALCL might be the substitution for TCR-mediated
signaling, since most components of the T cell receptor complex are down-regulated to
some extent in ALCL [12,14]. In fact, substitution of TCR signaling might be required at
least at some point of ALCL pathogenesis [55]. In this context, it is interesting to note
that ALCL regularly develops at sites of chronic, possibly non-specific antigen stimulation,
for example, breast implants or insect bites [56,57], suggesting a link between chronic T
cell stimulation and ALCL pathogenesis. Even more intriguing, aberrant expression or
maintenance of CD74 and its fragment CLIP on solid tumor cells and lymphoma models
prevents presentation of tumor antigens and favors an immune escape [58–60], which could
contribute to prevention of an effective anti-lymphoma immune response in ALCL. Apart
from effects on cell growth and survival, the aberrant expression of MHC-II-associated
regulators such as CTIIA alters T cell polarization [61], which might contribute to the
ALCL phenotype. Furthermore, the influence of CD74 on NF-κB or AP-1 activation [30,35]
in ALCL needs to be determined in future studies. As an additional tool for possible
therapeutic interventions in ALCL, we demonstrated in this study MET expression in a
subset of cases. MET is known to form signaling complexes with CD74 [33,46], and can
be activated by CD74 engagement [62]. Although we did not observe an effect of MET
inhibitors on ALCL cell viability, the functional role of MET, alone or in the context of CD74
signaling, in ALK+ ALCL has to be investigated in future studies.
Taken together, our data extend the spectrum of CD74-positive diseases to ALK+ and
ALK− ALCL. Given the usually limited prognosis of subgroups of these lymphoma entities
and of relapsed and refractory disease, CD74 and its associated signaling components
represent promising candidates for the development of new therapeutic strategies for these
T cell-derived malignancies.
5. Conclusions
In conclusion, our findings support the concept that ALK+ and ALK− ALCL share
a common molecular basis of transformation. More specifically, we describe robust ex-
pression of CD74, also known as the invariant chain of major histocompatibility complex
[MHC]-II, in ALCL regardless of t(2;5). The fact that CD74 ligation induces cell death of
ALCL cells and enhances the cytotoxic effects of chemotherapeutics or the ALK inhibitor
crizotinib in ALCL cell lines, as well as the efficient killing of CD74-positive ALCL cell
lines by a CD74-targeting antibody-drug conjugate, all point to the exploration of CD74 as
a therapeutic tool for ALCL. In addition, we demonstrated MET-expression in a subset of
ALCL cases. Together, these data provide new insights into ALCL biology and might help
to identify new targets for the development of treatment strategies for this lymphoma type.
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